Form 4: Inhibitor Therapeutics Director Ronald Osman Acquires 50,000 Shares of Restricted Common Stock
SEC Form 4
Director Ronald Osman acquired 50,000 shares of Inhibitor Therapeutics' restricted common stock as compensation on April 1, 2024.
Summary
- On April 1, 2024, Ronald E. Osman, a director and 10% owner of Inhibitor Therapeutics, Inc. (INTI), acquired 50,000 shares of common stock.
- The acquisition was made through the issuance of restricted common stock as compensation under the company's 2014 Equity Incentive Plan.
- The price per share was $0.
- Following the transaction, Mr. Osman directly owns 100,000 shares and indirectly owns 23,564,985 shares through The Ronald E. Osman Trust III, for which he serves as the sole trustee.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock acquisition by a director as part of a compensation plan. While insider buying can be seen as positive, this is part of a pre-existing plan.
Positives
- The acquisition of shares by a director could be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in the biopharmaceutical industry where equity compensation is frequently used.
Comparison to Industry Standards
- Equity compensation is a standard practice in the biotech industry to align the interests of management with those of shareholders.
- Comparing the size of this grant to similar companies would require analyzing their compensation structures and equity incentive plans.
- Without more information about Inhibitor Therapeutics' overall compensation strategy, it's difficult to assess whether this grant is above or below industry benchmarks.
Stakeholder Impact
- The acquisition of shares by a director could increase shareholder confidence.
Key Dates
| Date | Description |
|---|---|
| 04/01/2024 | Date of transaction: Ronald Osman acquired 50,000 shares of restricted common stock. |
| 05/16/2024 | Date of report filing. |
Keywords
Inhibitor Therapeutics, INTI, Ronald Osman, Director, 10% Owner, Stock Acquisition, Restricted Stock, Equity Incentive Plan, Beneficial Ownership, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.